Imfinzi (durvalumab) - AstraZeneca
Alecensa (alectinib) - Roche
Datroway (datopotamab deruxtecan-dlnk) - Daiichi Sankyo, AstraZeneca
Rozlytrek (entrectinib) - Roche
Tecentriq (atezolizumab) - Roche
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
rilvegostomig (AZD2936) - AstraZeneca
Keytruda (pembrolizumab) - Merck (MSD)
Hernexeos (zongertinib) - Boehringer Ingelheim
https://www.ispor.org/conferences-education/conferences/upcoming-conferences/ispor-2026/program/program/session/ispor-2026/pros-and-patient-preference-poster-tour
 
Trupti Dhumal; Sahil Bhave; Emma van Eijndhoven; Ambarish J. Ambegaonkar
 
Mar 6, 2026
 
Prev Next